# Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

> **NCT07715734** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 22 (estimated)

## Conditions studied

- Kidney Transplant Recipient
- Cutaneous Squamous Cell Carcinoma (CSCC)
- Advanced Cutaneous Squamous Cell Carcinoma
- Kidney Transplant

## Interventions

- **DRUG:** Cemiplimab
- **DRUG:** Prednisone
- **DRUG:** Sirolimus
- **DRUG:** Cetuximab (EGFR inhibitor)

## Key facts

- **NCT ID:** NCT07715734
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-30
- **Primary completion:** 2031-03-31
- **Final completion:** 2031-03-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07715734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07715734, "Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07715734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*